拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMRN 拜玛林制药

交易中 02-20 15:48:12 EST

63.95

+0.53

+0.84%

最高64.14	最低62.55	成交量241.07万
今开62.55	昨收63.42	日振幅2.51%
总市值122.86亿	流通市值113.90亿	总股本1.92亿
成交额1.53亿	换手率1.35%	流通股本1.78亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMRN","market":"US","secType":"STK","nameCN":"拜玛林制药","latestPrice":63.95,"timestamp":1771620490868,"preClose":63.42,"halted":0,"volume":2410692,"delay":0,"changeRate":0.008356985178177248,"floatShares":178100339,"shares":192114344,"eps":2.680754,"marketStatus":"交易中","change":0.53,"latestTime":"02-20 15:48:12 EST","open":62.55,"high":64.14,"low":62.55,"amount":153389342.70192,"amplitude":0.025071,"askPrice":63.99,"askSize":14,"bidPrice":63.96,"bidSize":30,"shortable":3,"etf":0,"ttmEps":2.680754,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1771621200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":932702400000,"exchange":"NASDAQ","adjPreClose":63.42,"preHourTrading":{"tag":"盘前","latestPrice":63.44,"preClose":63.42,"latestTime":"08:00 EST","volume":1,"amount":63.44,"timestamp":1771592401412,"change":0.02,"changeRate":0.000315,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":63.32,"preClose":63.42,"latestTime":"19:53 EST","volume":41850,"amount":2654059.8299,"timestamp":1771548811082,"change":-0.1,"changeRate":-0.001577,"amplitude":0.002838},"volumeRatio":0.98548,"impliedVol":0.4892,"impliedVolPercentile":0.9163},"requestUrl":"/m/hq/s/BMRN","defaultTab":"news","newsList":[{"id":"1158176505","title":"拜玛林制药Voxzogo®获加拿大卫生部附条件批准 用于软骨发育不全症治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1158176505","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158176505?lang=zh_cn&edition=full","pubTime":"2026-02-11 20:10","pubTimestamp":1770811832,"startTime":"0","endTime":"0","summary":"拜玛林制药（Biomarin Pharmaceutical）近日宣布，其治疗软骨发育不全症的药物Voxzogo®已获得加拿大卫生部颁发的附条件合规通知。这一批准标志着该药物在加拿大市场迈出重要一步，为当地患者提供了新的治疗选择。\n软骨发育不全症是一种罕见的遗传性疾病，主要特征为骨骼发育异常。Voxzogo®作为一种创新疗法，其获批将为符合特定条件的患者群体带来希望。加拿大卫生部的附条件批准通常基于药物显示的潜在临床效益，同时要求制药公司继续开展相关研究以进一步验证疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","BK4566","BMRN","IE0002270589.USD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","BK4139"],"gpt_icon":0},{"id":"1103610111","title":"拜玛林制药敲定高级票据私募发行价格，并完成新高级担保定期贷款银团组建","url":"https://stock-news.laohu8.com/highlight/detail?id=1103610111","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103610111?lang=zh_cn&edition=full","pubTime":"2026-01-30 05:06","pubTimestamp":1769720774,"startTime":"0","endTime":"0","summary":"拜玛林制药已确定其高级票据的私募发行价格，同时宣布成功组建新的高级担保定期贷款银团。这两项融资举措的完成，标志着公司在优化资本结构方面取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","BK4566","BK4139","BMRN","IE00B7SZLL34.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"1199936217","title":"拜玛林制药宣布拟进行优先票据私募发行并启动新优先担保定期贷款银团融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1199936217","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199936217?lang=zh_cn&edition=full","pubTime":"2026-01-26 20:47","pubTimestamp":1769431635,"startTime":"0","endTime":"0","summary":"拜玛林制药(BMRN)最新披露，公司将启动两项重要融资安排：一方面计划以非公开方式发行优先票据，另一方面正牵头组织新的优先担保定期贷款银团融资项目。\n该生物制药巨头通过双重融资策略优化资本结构，优先票据私募发行将面向合格机构投资者，而银团贷款方案则通过联合多家金融机构共同提供资金支持。这两项融资举措将为企业研发管线推进和全球业务扩张提供战略性资金保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BK4139","BMRN","BK4566"],"gpt_icon":0},{"id":"1102753463","title":"Canaccord Genuity上调拜玛林制药评级至买入 目标价大幅提升至98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102753463","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102753463?lang=zh_cn&edition=full","pubTime":"2026-01-20 13:27","pubTimestamp":1768886841,"startTime":"0","endTime":"0","summary":"投资机构Canaccord Genuity近日发布最新研报，将拜玛林制药（Biomarin Pharmaceutical）的投资评级从\"持有\"显著上调至\"买入\"级别。与此同时，该机构将其目标股价从原先的84美元大幅调升至98美元，显示出对该公司未来发展的强烈信心。\n此次评级调整反映了分析师对拜玛林制药核心业务增长前景的乐观预期。目标价的大幅提升也预示着该机构认为公司股价具备可观的上涨空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","BK4566","BMRN","IE0002270589.USD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","BK4139"],"gpt_icon":0},{"id":"1122318998","title":"拜玛林制药 - 停止开发口服治疗阿尔法-1抗胰蛋白酶缺乏症（AATD）的Bmn 349 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1122318998","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122318998?lang=zh_cn&edition=full","pubTime":"2025-12-22 22:08","pubTimestamp":1766412526,"startTime":"0","endTime":"0","summary":"拜玛林制药 - 停止开发口服治疗阿尔法-1抗胰蛋白酶缺乏症（AATD）的Bmn 349 - SEC文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BK4139","BMRN","BK4566","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"1187502050","title":"拜玛林制药：根据合并协议终止，阿米库斯将支付拜玛林1.75亿美元的终止费用 - SEC提交文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1187502050","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187502050?lang=zh_cn&edition=full","pubTime":"2025-12-19 21:52","pubTimestamp":1766152334,"startTime":"0","endTime":"0","summary":"拜玛林制药：根据合并协议终止，阿米库斯将支付拜玛林1.75亿美元的终止费用 - SEC提交文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","IE00B7SZLL34.SGD","BK4566","IE00B19Z3B42.SGD","IE0002270589.USD","BMRN","BK4139"],"gpt_icon":0},{"id":"1191463279","title":"爱美医疗股价在盘前交易中上涨30%，拜玛林制药将以48亿美元收购该公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1191463279","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191463279?lang=zh_cn&edition=full","pubTime":"2025-12-19 21:13","pubTimestamp":1766149995,"startTime":"0","endTime":"0","summary":"爱美医疗股价在盘前交易中上涨30%，拜玛林制药将以48亿美元收购该公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU2065171311.SGD","IE00B7SZLL34.SGD","LU2065169927.USD","FOLD","BMRN","IE00B19Z3B42.SGD","IE0002270589.USD","BK4139","LU2065171402.SGD","LU2065170008.USD","BK4566"],"gpt_icon":0},{"id":"1174007364","title":"拜玛林制药以48亿美元收购爱美医疗，巩固稀有疾病领域的领导地位，推动收入增长，增强财务前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1174007364","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174007364?lang=zh_cn&edition=full","pubTime":"2025-12-19 20:52","pubTimestamp":1766148765,"startTime":"0","endTime":"0","summary":"拜玛林制药以48亿美元收购爱美医疗，巩固稀有疾病领域的领导地位，推动收入增长，增强财务前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2065171311.SGD","IE00B19Z3581.USD","BK4566","LU2065171402.SGD","LU2065169927.USD","IE00B19Z3B42.SGD","BMRN","IE0002270589.USD","FOLD","IE00B7SZLL34.SGD","LU2065170008.USD"],"gpt_icon":0},{"id":"1159090067","title":"爱美医疗将于2037年1月30日授予Aurobindo和Lupin在美国市场销售Galafold的仿制药许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1159090067","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159090067?lang=zh_cn&edition=full","pubTime":"2025-12-19 20:52","pubTimestamp":1766148759,"startTime":"0","endTime":"0","summary":"爱美医疗将于2037年1月30日授予Aurobindo和Lupin在美国市场销售Galafold的仿制药许可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B19Z3B42.SGD","BK4566","LU2065170008.USD","LU2065171402.SGD","IE0002270589.USD","LU2065171311.SGD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","LU2065169927.USD","FOLD","BMRN"],"gpt_icon":0},{"id":"1168785237","title":"爱美医疗：交易将于2027年开始显著提升拜玛林制药的非GAAP稀释每股收益","url":"https://stock-news.laohu8.com/highlight/detail?id=1168785237","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168785237?lang=zh_cn&edition=full","pubTime":"2025-12-19 20:48","pubTimestamp":1766148494,"startTime":"0","endTime":"0","summary":"爱美医疗：交易将于2027年开始显著提升拜玛林制药的非GAAP稀释每股收益","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU2065171311.SGD","IE00B7SZLL34.SGD","LU2065169927.USD","FOLD","BMRN","IE00B19Z3B42.SGD","IE0002270589.USD","BK4139","LU2065171402.SGD","LU2065170008.USD","BK4566"],"gpt_icon":0},{"id":"1168884106","title":"摩根士丹利：这些“潜在分红股”若启动派息，或将带来可观回报","url":"https://stock-news.laohu8.com/highlight/detail?id=1168884106","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168884106?lang=zh_cn&edition=full","pubTime":"2025-11-11 11:20","pubTimestamp":1762831244,"startTime":"0","endTime":"0","summary":"根据摩根士丹利的分析，一些美股公司具备财务实力，有能力开始向股东支付股息。为了寻找这些“潜在分红股”，卡斯塔尼奥筛选出了那些目前尚未支付季度股息、净现金占市值比例超过5%、自由现金流收益率高于3%的公司。摩根士丹利指出，Schwab的净现金占市值比例为12.3%，自由现金流收益率为8.7%。其股价年初至今上涨约29%。Twilio预计2025年的自由现金流将在9.2亿至9.3亿美元之间。其股价今年迄今上涨近21%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/5f85c955e3208ef4eece8dcd45934bb7","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/5f85c955e3208ef4eece8dcd45934bb7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1a9184b88c2cdb4d7f1e15ff04a6a973","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DDS","LYFT","CART","INCY","SCHW","NYT","ABNB","TWLO","BMRN","SAM"],"gpt_icon":1},{"id":"2578966978","title":"BioMarin为其药物VOXZOGO设定2025年9-9.35亿美元营收目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2578966978","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578966978?lang=zh_cn&edition=full","pubTime":"2025-10-28 23:00","pubTimestamp":1761663632,"startTime":"0","endTime":"0","summary":"美股周二早盘，生物技术企业BioMarin Pharmaceutical （BMRN）股价上涨4.4%，此前该公司为其药物VOXZOGO设定2025年9-9.35亿美元营收目标。尽管整体业务表现强劲，公司仍计划剥离ROCTAVIAN产品以聚焦战略重点。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-10-28/doc-infvnhpi1031324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["IE00B19Z3581.USD","IE00B7SZLL34.SGD","BK4566","IE00B19Z3B42.SGD","SINA","IE0002270589.USD","BMRN","BK4139"],"gpt_icon":0},{"id":"1126115775","title":"拜玛林制药：将在美国、意大利和德国继续商业供应Roctavian，直至下一步措施确定","url":"https://stock-news.laohu8.com/highlight/detail?id=1126115775","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126115775?lang=zh_cn&edition=full","pubTime":"2025-10-28 04:23","pubTimestamp":1761596631,"startTime":"0","endTime":"0","summary":"拜玛林制药：将在美国、意大利和德国继续商业供应Roctavian，直至下一步措施确定","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","BK4566","BK4139","IE00B7SZLL34.SGD","BMRN"],"gpt_icon":0},{"id":"1180747900","title":"拜玛林制药第三季度预计因Inozyme Pharma交易产生约1.10美元的GAAP和非GAAP每股收益费用","url":"https://stock-news.laohu8.com/highlight/detail?id=1180747900","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180747900?lang=zh_cn&edition=full","pubTime":"2025-10-08 05:22","pubTimestamp":1759872151,"startTime":"0","endTime":"0","summary":"拜玛林制药公司表示，预计第三季度因Inozyme Pharma交易将对GAAP和非GAAP每股收益产生约1.10美元的费用影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","BK4139","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BK4566","BMRN"],"gpt_icon":0},{"id":"1169021884","title":"拜玛林制药：预计第三季度将因收购Inoozyme Pharma交易产生约2.21亿美元税前已收购研发资产费用","url":"https://stock-news.laohu8.com/highlight/detail?id=1169021884","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169021884?lang=zh_cn&edition=full","pubTime":"2025-10-08 05:20","pubTimestamp":1759872020,"startTime":"0","endTime":"0","summary":"拜玛林制药预计，由于收购Inoozyme Pharma的交易，第三季度将产生约2.21亿美元的已收购研发资产费用（税前基础）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","BK4566","BMRN","IE0002270589.USD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","BK4139"],"gpt_icon":0},{"id":"1108040225","title":"拜玛林制药：H.C. Wainwright首次覆盖并给予中性评级，目标价60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108040225","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108040225?lang=zh_cn&edition=full","pubTime":"2025-09-08 18:48","pubTimestamp":1757328496,"startTime":"0","endTime":"0","summary":"拜玛林制药：H.C. Wainwright首次覆盖并给予中性评级，目标价60美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BK4139","BMRN","BK4566"],"gpt_icon":0},{"id":"1174292197","title":"Biomarin在第15届先天性代谢病国际大会上公布Palynziq®(Pegvaliase-Pqpz)治疗青少年苯丙酮尿症关键3期试验的积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1174292197","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174292197?lang=zh_cn&edition=full","pubTime":"2025-09-06 23:21","pubTimestamp":1757172077,"startTime":"0","endTime":"0","summary":"Biomarin在第15届先天性代谢病国际大会上宣布，其药物Palynziq®(Pegvaliase-Pqpz)用于治疗青少年苯丙酮尿症患者的关键性3期临床试验获得积极结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BK4139","IE00B19Z3581.USD","BMRN"],"gpt_icon":0},{"id":"1159302131","title":"拜玛林制药：Raymond James首次覆盖并给予跑赢大盘评级，目标价85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159302131","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159302131?lang=zh_cn&edition=full","pubTime":"2025-09-03 19:56","pubTimestamp":1756900608,"startTime":"0","endTime":"0","summary":"Raymond James开始覆盖拜玛林制药，给予该股跑赢大盘评级，并设定目标价为85美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN","IE00B7SZLL34.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","BK4566","IE00B19Z3581.USD","BK4139"],"gpt_icon":0},{"id":"2513372995","title":"奥本海默：上调Biomarin Pharmaceutical(BMRN.US)评级，由Perform调整至优于大市评级, 目标价98.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513372995","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513372995?lang=zh_cn&edition=full","pubTime":"2025-02-24 21:17","pubTimestamp":1740403022,"startTime":"0","endTime":"0","summary":"奥本海默：上调Biomarin Pharmaceutical(BMRN.US)评级，由Perform调整至优于大市评级, 目标价98.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/24211748352370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BMRN"],"gpt_icon":0},{"id":"1111972741","title":"异动解读 | 财报远超预期,拜玛林制药盘前大涨10.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111972741","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111972741?lang=zh_cn&edition=full","pubTime":"2025-02-20 18:18","pubTimestamp":1740046705,"startTime":"0","endTime":"0","summary":"2025年第四季度财报出炉,拜玛林制药公司大幅超过了市场预期,这一利好消息推动公司股价在今日盘前大涨10.52%。\n\n拜玛林制药此前公布的2025年第四季度每股收益为0.92美元,远高于市场预期的0.53美元;季度销售额也创下7.4731亿美元的新高。此番罕见的业绩喜讯,令投资者看好公司进一步发展前景。\n\n作为领先的罕见疾病专业制药企业,拜玛林制药的出色表现得益于其管线和产品创新所带来的增长。投资界普遍认为,在需求不断增长的罕见疾病领域,公司将凭借领先优势开发新药并扩大收入来源,高速增长将延续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BMRN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bmrn.com","stockEarnings":[{"period":"1week","weight":0.0581},{"period":"1month","weight":0.1263},{"period":"3month","weight":0.1596},{"period":"6month","weight":0.0826},{"period":"1year","weight":-0.0334},{"period":"ytd","weight":0.0671}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0102},{"period":"3month","weight":0.0386},{"period":"6month","weight":0.0607},{"period":"1year","weight":0.1167},{"period":"ytd","weight":0.0038}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biomarin Pharmaceutical Inc.于1996年10月在特拉华州注册成立，并于1997年3月21日开始运营。该公司是一家全球性生物技术公司，致力于将基因发现的前景转化为对每位患者的生活产生深远影响的药物。T. BioMarin为代表重大未满足医疗需求的疾病和病症选择候选产品，这些疾病和病症具有很好的生物学理解，并提供了率先上市或提供优于现有产品的机会。该公司的产品组合由四个已获批准的产品和多个研究候选产品组成。","yearOnYearQuotes":[{"month":1,"riseRate":0.62963,"avgChangeRate":0.046047},{"month":2,"riseRate":0.481481,"avgChangeRate":0.017243},{"month":3,"riseRate":0.461538,"avgChangeRate":0.004784},{"month":4,"riseRate":0.5,"avgChangeRate":-0.018877},{"month":5,"riseRate":0.5,"avgChangeRate":0.006184},{"month":6,"riseRate":0.615385,"avgChangeRate":0.016976},{"month":7,"riseRate":0.653846,"avgChangeRate":0.039526},{"month":8,"riseRate":0.555556,"avgChangeRate":0.001992},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.012768},{"month":10,"riseRate":0.407407,"avgChangeRate":-0.026394},{"month":11,"riseRate":0.814815,"avgChangeRate":0.061245},{"month":12,"riseRate":0.62963,"avgChangeRate":0.034544}],"exchange":"NASDAQ","name":"拜玛林制药","nameEN":"Biomarin Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拜玛林制药,BMRN,拜玛林制药股票,拜玛林制药股票老虎,拜玛林制药股票老虎国际,拜玛林制药行情,拜玛林制药股票行情,拜玛林制药股价,拜玛林制药股市,拜玛林制药股票价格,拜玛林制药股票交易,拜玛林制药股票购买,拜玛林制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}